Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 58 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Breaking News: Supreme Court Upholds the Affordable Care Act June 17, 2021 Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for... May 19, 2026 How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... August 23, 2022 Load more HOT NEWS How Your Primary Care Provider Can Help You Throughout Your Cancer... Time to get stratified After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19
